Diabetes · Phase 2
Zenagamtide: oral and subcutaneous diabetes cohorts
What was tested?
Oral or subcutaneous zenagamtide, formerly amycretin, compared with matching placebo within route cohorts. ↗
Registered primary question: Change in HbA1c from baseline to week 36. ↗
What the reviewed report found
Oral zenagamtide: phase 2 diabetes cohort · Journal year 2026 · Article summary reviewed 2026-09-15
All three active groups improved glycated hemoglobin compared with placebo. Gastrointestinal events were common; seven participants in active groups had serious adverse events.↗
Subcutaneous zenagamtide: phase 2 diabetes cohort · Journal year 2026 · Article summary reviewed 2026-09-15
Active groups improved glycated hemoglobin compared with placebo. Gastrointestinal adverse events were common; serious adverse events were reported in active and placebo groups.↗
Keep in context: Both reports share NCT06542874: 186 participants in the oral cohort and 262 in the subcutaneous cohort. They are two route reports within one registered study, not independent trial replications. ↗↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 448 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years to 75 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-08-13; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Oral zenagamtide: phase 2 diabetes cohort
- Design in the report
- A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.↗
- Participants in the report
- This report included 186 adults with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor.↗
- Limitations
- The primary analysis used on-treatment data without rescue medication. Glycemic improvement does not establish reduction in long-term complications; this cohort shares a protocol with the subcutaneous report.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
Subcutaneous zenagamtide: phase 2 diabetes cohort
- Design in the report
- A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.↗
- Participants in the report
- This route cohort randomized 262 adults with type 2 diabetes; 261 received treatment.↗
- Limitations
- This is a route cohort within the same protocol as the oral report, not evidence from an unrelated replication. Follow-up and surrogate endpoints limit conclusions about long-term outcomes.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes ↗
Protocol identifier: NN9490-7678. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 66a86d4831f8b91dd76aa57036e579f8df1978cbcb1b9c21f589b86810a36365.
PMID 42532079
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42532079. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 a38bd67eb9127a41fddef95e4d6e879023591b667ddbfd8eb6531901dc42557b.
PMID 42532080
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42532080. SHA-256 7e3cd4cb35b2e5abb058fcf9f23f48e83e61e5ce248a821aa545ec71b48b435b.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 bd2779fa1150d5ab1787f5a245e06368e1aa73edf5c6310f340e154d500e222e.